Leuven, Belgium. ThromboGenics announces that further ocriplasmin clinical data will be presented at the 34th Annual Scientific Meeting of the American Society of Retina Specialists. The Meeting is being held from August, 9th through August 14th, 2016 in San Francisco, California.
Wednesday 10th August
12:55 - 1:35 PM Macular Surgery Symposium
12:55 ORBIT: A Phase IV Clinical Study: Lessons Learned From Patient Selection Criteria for Ocriplasmin Intravitreal Injection, by Mathew MacCumber, MD, PhD
1:35 - 1:55 PM Macular Surgery Symposium—Rapid Fire Papers
1:35 The OASIS Trial: Natural History of Symptomatic Vitreomacular Adhesion, by Joseph Coney, MD
1:40 The OASIS Trial: Efficacy and Safety Outcomes in Subjects With Full-Thickness Macular Hole, by Michael Tolentino, MD
The presentations will cover data from ORBIT, an ocriplasmin Phase IV clinical study, and from the OASIS randomized trial, a 2 year follow-up study evaluating Ocriplasmin for the treatment of symptomatic VMA (VMT) including macular hole.
Dr Patrik De Haes, CEO of ThromboGenics nv, comments, “We are delighted to have the opportunity to share our research at the American Society of Retina Specialists this year. ThromboGenics is committed to high-quality fundamental research in the field of ophthalmology and to development of a number of next-generation ophthalmology products.”